AbstractFunctional loss of p53 and ErbB2 overexpression are the frequent genetic alterations in human breast carcinomas. Here, we found that ErbB2 expression was upregulated in primary cultured mammary epithelial cells (MECs) isolated from mice with a defect in exons 5 and 6 of the p53 gene (p53Δ5,6). The reporter gene activity in the p53Δ5,6 MECs transfected with the −756bp flanking region of the hErbB2 gene was higher than the wild type MECs. p53 inactivation selectively increased the level of AP-2α, but not AP-2β and AP-2γ and a mutation of the two AP-2 binding sites completely inhibited the reporter activity
Approximately 70 % of human breast cancers are estrogen receptor! (ER!)-positive, but the origins of...
Introduction of the normal erbB-2 gene into immortalized human mammary epithelial cells (184B5) by t...
Estrogen receptor (ER) and the tumor suppressor p53 are key prognostic indicators in breast cancer. ...
AbstractFunctional loss of p53 and ErbB2 overexpression are the frequent genetic alterations in huma...
Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleratio...
The ERBB2 gene is overexpressed in 30% of breast cancers and this has been correlated with poor prog...
The proto-oncogene ErbB2 is overexpressed and amplified in 20-30% of human breast cancers, and was i...
SummaryErbB2 gene amplification occurs in 20%–25% of breast cancers, and its therapeutic targeting h...
Abstract Background Upregulation of estrogen receptor beta (ERβ) in breast cancer cells is associate...
Understanding the mechanisms underlying tumour heterogeneity is key to the development of treatments...
AbstractBackgroundMost breast cancers express the estrogen receptor alpha (ERα+), harbor wt TP53, de...
The negative-regulatory feedback loop between p53 and hdm2 forms part of a finely balanced regulator...
Amplification and overexpression of ErbB2 strongly correlates with aggressive breast cancers. A deep...
AbstractAberrations of p53 occur in most, if not all, human cancers. In breast cancer, p53 mutation ...
Defective autophagy has been implicated in mammary tumorigenesis, as the gene encoding the essential...
Approximately 70 % of human breast cancers are estrogen receptor! (ER!)-positive, but the origins of...
Introduction of the normal erbB-2 gene into immortalized human mammary epithelial cells (184B5) by t...
Estrogen receptor (ER) and the tumor suppressor p53 are key prognostic indicators in breast cancer. ...
AbstractFunctional loss of p53 and ErbB2 overexpression are the frequent genetic alterations in huma...
Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleratio...
The ERBB2 gene is overexpressed in 30% of breast cancers and this has been correlated with poor prog...
The proto-oncogene ErbB2 is overexpressed and amplified in 20-30% of human breast cancers, and was i...
SummaryErbB2 gene amplification occurs in 20%–25% of breast cancers, and its therapeutic targeting h...
Abstract Background Upregulation of estrogen receptor beta (ERβ) in breast cancer cells is associate...
Understanding the mechanisms underlying tumour heterogeneity is key to the development of treatments...
AbstractBackgroundMost breast cancers express the estrogen receptor alpha (ERα+), harbor wt TP53, de...
The negative-regulatory feedback loop between p53 and hdm2 forms part of a finely balanced regulator...
Amplification and overexpression of ErbB2 strongly correlates with aggressive breast cancers. A deep...
AbstractAberrations of p53 occur in most, if not all, human cancers. In breast cancer, p53 mutation ...
Defective autophagy has been implicated in mammary tumorigenesis, as the gene encoding the essential...
Approximately 70 % of human breast cancers are estrogen receptor! (ER!)-positive, but the origins of...
Introduction of the normal erbB-2 gene into immortalized human mammary epithelial cells (184B5) by t...
Estrogen receptor (ER) and the tumor suppressor p53 are key prognostic indicators in breast cancer. ...